Showing 1701-1710 of 3223 results for "".
- AMA: Look to Ophthalmology for a Glimpse of Telemedicine’s Futurehttps://modernod.com/news/ama-look-to-ophthalmology-for-a-glimpse-of-telemedicines-future/2479477/Early on in the COVID-19 pandemic, ophthalmology struggled to adapt to telemedicine. It just wasn’t set up for virtual visits. “Ophthalmology is an exam-heavy specialty, and we really rely on all the clinical clues that we capture—either at the slit lamp, or looking at the retina, or check
- Hillrom Introduces Next-Generation Technology In Fight Against Diabetic Retinopathyhttps://modernod.com/news/hillrom-introduces-next-generation-technology-in-fight-against-diabetic-retinopathy/2476777/Hillrom announced its latest innovation in vision screening and diagnostics with the introduction of the Welch Allyn RetinaVue 700 Imager handheld retinal camera, which enables remote ophthalmologists to diagnose diabetic retinopathy during routine primary care office visits. “Our n
- Nicox Announces Data Collection Complete, NCX 470 Phase 3b Whistler Glaucoma Trialhttps://modernod.com/news/nicox-announces-data-collection-complete-ncx-470-phase-3b-whistler-glaucoma-trial/2482709/Nicox announced today that the last patient completed their final visit in the Whistler phase 3b clinical trial investigating the efficacy of NCX470 to lower IOP. This marks the end of their
- Medicare Sticks With E/M Pay Plan Over Some Groups’ Objectionshttps://modernod.com/news/medicare-sticks-with-e-m-pay-plan-over-some-groups-objections/2478136/The Trump administration is sticking with a plan to boost certain Medicare pay for many primary care and other specialties focused heavily on office visits while lowering that for other groups to balance these increased costs, according to a Medscape
- Analysis: Ophthalmology Lost More Patient Volume Due to COVID-19 Than Any Other Specialtyhttps://modernod.com/news/analysis-55-percent-fewer-americans-sought-hospital-care-in-march-april-due-to-covid-19/2477738/A new large analysis revealed that ophthalmology lost more patient volume due to the COVID-19 pandemic than any other medical specialty. The analysis of over 2 million patient visits and encounters
- New 10 Year Warranty for Haag-Streit Slit Lampshttps://modernod.com/news/new-10-year-warranty-for-haag-streit-slit-lamps/2479858/As of October 2018, Haag-Streit Diagnostics is introducing a 10 year limited warranty for its slit lamps. For more information on Haag-Streit’s slit lamps and the new warranty program, visit
- RetinalGeniX Technologies Acquires DNA/GPS Inc.https://modernod.com/news/retinalgenix-technologies-acquires-dnagps-inc/2480949/RetinalGeniX Technologies announced the acquisition of DNA/GPS. Terms of the deal were not disclosed. The acquisition gives RetinalGeniX the rights to the platform technology designed by Larry Perich, MD, which is designed to al
- Harrow Launches 'Vevye Access for All' to Reduce Patient Barriers for Dry Eye Disease Treatmenthttps://modernod.com/news/harrow-launches-vevye-access-for-all-reducing-patient-barriers-for-dry-eye-disease-treatment/2482703/Harrow announced 'Vevye Access For All' – a new initiative that aims to reduce patient barriers to dry eye disease treatment. Harrow partnered with specialty pharmacy PhilRx to offer Vevye (cyclosporine ophthalmic solution) 0.1% for eligible patients at $59 a bottle. The g
- Business Executive Alex Gorsky Joins Neurotech’s Board as Lead Directorhttps://modernod.com/news/business-executive-alex-gorsky-joins-neurotechs-board-as-lead-director/2481827/Neurotech Pharmaceuticals announced that Alex Gorsky has been elected to Neurotech’s board as Lead Director. Mr. Gorsky is the former Chairman and CEO of Johnson & Johnson. Under Mr. Gorsky’s leadership, Johnson & Johnson grew to become one of world’s larg
- Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Activehttps://modernod.com/news/dopavision-provides-clinical-trial-update-and-announces-all-myopiax-1-trial-sites-are-active/2481699/Dopavision announced an update on its MyopiaX-1 trial (NCT04967287). All clinical trial centers are now open and are actively screening and enrolling study participants, providing trial access to eligible children with myopia across Germany, Spain, the Netherlands, and the United Kingdom.